A Phase II Trial of Vincristine in Advanced or Recurrent Endometrial Carcinoma A Gynecologic Oncology Group Study

Abstract

Thirty-three evaluable patients who had not received prior chemotherapy were entered on a study of vincristine therapy for advanced or recurrent endometrial carcinoma. Vincristine 1.4 mg/m² was given weekly as an i.v. bolus for 4 weeks and then every other week. There was one complete response (CR) lasting 5 months. Five patients had partial responses (PR) lasting 3–18 months. The CR + PR rate was 18% (95% confidence interval for CR + PR was 7–36%). Thirteen patients (38%) had stable disease from 2–28 months, and 14 had progressive disease. The major toxicity was neurological, with 11 patients having grade 2 or 3 peripheral neuropathy. Vincristine at this dose and schedule has modest activity, but troublesome toxicity in advanced or recurrent endometrial carcinoma.